Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,727 active trials51 approved drugs619 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,611 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06008093 | A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS(TRITON) | active not recruiting | Phase 2 | 103 | AstraZenecaINDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer Center |
| 1 |
| Jul 2, 2026 |
| clinicaltrials |
| NCT07176559 | Pilot Randomized Clinical Trial of Informational Support Versus Spiritual Care(PRaCTIS) | active not recruiting | N/A | 36 | Indiana UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04227028 | Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC | active not recruiting | Phase 1 | 5 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04655976 | Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy(COSTAR Lung) | active not recruiting | Phase 2 / Phase 3 | 758 | GlaxoSmithKlineINDUSTRY | 24 | Jul 1, 2026 | clinicaltrials |
| NCT05118854 | A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation | active not recruiting | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06015724 | Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer(DARANIVOVAX) | active not recruiting | Phase 2 | 19 | Georgetown UniversityOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05164757 | Female Asian Nonsmoker Screening Study(FANSS) | active not recruiting | — | 1,041 | NYU Langone HealthOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05478538 | Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (ELEPHAS-01)(ELEPHAS-01) | active not recruiting | — | 200 | ElephasINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05520099 | Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)(ELEPHAS-02) | active not recruiting | — | 416 | ElephasINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04536675 | Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery | active not recruiting | Phase 3 | 204 | Samsung Medical CenterOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06227546 | MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer(MGC018-SCLC) | active not recruiting | Phase 2 | 9 | Georgetown UniversityOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07457541 | Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI | active not recruiting | Phase 1 | 15 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07669051 | A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment | active not recruiting | Phase 2 | 36 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05555732 | Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) | active not recruiting | Phase 3 | 1,170 | Daiichi SankyoINDUSTRY | 29 | Jun 23, 2026 | clinicaltrials |
| NCT05609578 | Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation | active not recruiting | Phase 2 | 90 | Mirati Therapeutics Inc.INDUSTRY | 7 | Jun 23, 2026 | clinicaltrials |
| NCT05825625 | NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing | active not recruiting | Phase 2 | 35 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06219317 | Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC(ICARS) | active not recruiting | Phase 2 | 136 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Jun 23, 2026 | clinicaltrials |
| NCT03110978 | Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 140 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT03476681 | Study of NEO-201 in Solid Tumors Expansion Cohorts | active not recruiting | Phase 1 / Phase 2 | 121 | Precision Biologics, IncINDUSTRY | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05059522 | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | active not recruiting | Phase 3 | 77 | PfizerINDUSTRY | 19 | Jun 22, 2026 | clinicaltrials |
| NCT05143970 | A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors(CHANCES) | active not recruiting | Phase 1 | 27 | Institut Paoli-CalmettesOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05773092 | A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC | active not recruiting | Phase 2 | 30 | National Cancer Centre, SingaporeOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05221840 | A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer(PACIFIC-9) | active not recruiting | Phase 3 | 1,051 | AstraZenecaINDUSTRY | 20 | Jun 18, 2026 | clinicaltrials |
| NCT06055465 | Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 37 | Chinese University of Hong KongOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06257264 | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | active not recruiting | Phase 1 | 103 | BeiGeneINDUSTRY | 6 | Jun 18, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT04036682 | A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer(REZILIENT1) | active not recruiting | Phase 1 / Phase 2 | 284 | Cullinan Therapeutics Inc.INDUSTRY | 9 | Jun 17, 2026 | clinicaltrials |
| NCT06443684 | A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC | active not recruiting | — | 305 | Shanghai Chest HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05683977 | A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.(ARSENAL) | active not recruiting | — | 254 | AstraZenecaINDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06031558 | Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC | active not recruiting | Phase 3 | 120 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06501976 | An Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course Treatment | active not recruiting | Phase 2 | 9 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05358249 | Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation(KontRASt-03) | active not recruiting | Phase 1 / Phase 2 | 74 | Novartis PharmaceuticalsINDUSTRY | 8 | Jun 15, 2026 | clinicaltrials |
| NCT05565378 | A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer | active not recruiting | Phase 2 | 351 | GlaxoSmithKlineINDUSTRY | 22 | Jun 15, 2026 | clinicaltrials |
| NCT06245837 | Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic Alterations | active not recruiting | — | 1,500 | AstraZenecaINDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT00597636 | Genetic Susceptibility to Lung Cancer in Never Smokers | active not recruiting | — | 238 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT02503722 | Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 2 | Jun 11, 2026 | clinicaltrials |
| NCT04155034 | S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer | active not recruiting | Phase 3 | 668 | SWOG Cancer Research NetworkNETWORK | 7 | Jun 11, 2026 | clinicaltrials |
| NCT04214262 | Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer | active not recruiting | Phase 3 | 415 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04728230 | Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial | active not recruiting | Phase 1 / Phase 2 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04751747 | Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer | active not recruiting | N/A | 34 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07638228 | Evaluation of the Safety and Efficacy of a Wideband Electric Pulse Tumor Ablation System for Malignant Pulmonary Nodules | active not recruiting | N/A | 5 | Sir Run Run Shaw HospitalOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07638878 | The Efficacy of Tislelizumab Combined With Albumin-bound Paclitaxel and Platinum-based Chemotherapy in Patients With KRAS-mutated Lung Cancer | active not recruiting | — | 30 | Guangzhou Medical UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT02785952 | Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | active not recruiting | Phase 3 | 275 | SWOG Cancer Research NetworkNETWORK | 2 | Jun 9, 2026 | clinicaltrials |
| NCT01993810 | Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer | active not recruiting | Phase 3 | 330 | Radiation Therapy Oncology GroupNETWORK | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03137771 | Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 218 | NRG OncologyOTHER | 4 | Jun 8, 2026 | clinicaltrials |
| NCT03939481 | Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer | active not recruiting | — | 1,336 | SWOG Cancer Research NetworkNETWORK | 4 | Jun 8, 2026 | clinicaltrials |
| NCT04791839 | Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 30 | Washington University School of MedicineOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05789069 | A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 83 | HiFiBiO TherapeuticsINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT06308120 | A Trial to Compare Robotic Assisted Bronchoscopy Ion's Clinical Utility for Peripheral Lung Nodule Access and Diagnosis to ENB(ARTICULAtE) | active not recruiting | N/A | 354 | Intuitive SurgicalINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 2, 2026source: clinicaltrials